NUVB: Nuvation Bio - Update #10

Nuvation Bio released first quarter financial results on 5/4 after the close of trading. The company is gaining traction with new patients for lead drug Ibtrozi. The drug has been FDA approved for ROS1 NSCLC since June of 2025. Some key highlights from the first quarter results below. 

- 18.5 million in first quarter Ibtrozi revenue

- Greater than 50% of new patients were early line diagnosis

- China / Japan royalty revenue of $1.7 million

- Cash equivalents of $533.7 million

- Current Market cap of $1.5B

Essentially it was a breakeven quarter for Nuvation due to a one time collaboration payment from European partner Eisai, which combined with quarterly revenue, covered the research and SGA costs for the quarter. 

Second drug Safusidenib is currently in phase 3 testing with the SIGMA trial for high grade glioma, with expected completion around 2029. The trial can be viewed here NCT05303519. 

All prior Nuvation posts can be viewed here Nuvation Bio Posts. Thank you for reading.